phrykt

Silence Therapeutics plc (SLN): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of SLN were reported in the last 12 months. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Silence Therapeutics

From the latest filings

Overall: more buying than selling. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns SLN

69 funds and institutions reported SLN shares worth $249M at the end of Q2 2026, about 16% of the company. The largest holder is Siren, L.L.C. with 2.3%.

Funds and institutions (13F) 16%Everyone else 84%

10 largest owners, by share of the company

Siren, L.L.C.2.3%
TCG Crossover Management, LLC2.1%
Nantahala Capital Management, LLC1.9%
Redmile Group, LLC1.5%
Citadel Advisors LLC0.9%
Nextech Invest Ltd.0.7%
Millennium Management LLC0.6%
Tetragon Partners GP Ltd0.5%
Soleus Capital Management, L.P.0.4%
Balyasny Asset Management L.P.0.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Siren, L.L.C.3.31M2.34%$36.4M+14%
TCG Crossover Management, LLC3.03M2.14%$33.3MNo change
Nantahala Capital Management, LLC2.69M1.90%$29.6M+25%
Redmile Group, LLC2.16M1.53%$23.8MNo change
Citadel Advisors LLC1.33M0.94%$14.6M+8%
Nextech Invest Ltd.952,4000.67%$10.5MNo change
Millennium Management LLC909,2790.64%$10M-15%
Tetragon Partners GP Ltd764,2560.54%$8.4M+21%
Soleus Capital Management, L.P.630,0000.44%$6.9MNew
Balyasny Asset Management L.P.610,9800.43%$6.7MNew
5AM Venture Management, LLC476,2000.34%$5.2MNo change
Great Point Partners LLC450,0000.32%$4.9M-56%
Morgan Stanley403,1720.28%$4.4M+516%
Ameriprise Financial Inc370,0520.26%$4.1MNew
Jane Street Group, LLC369,1510.26%$4.1M+266%
ADAR1 Capital Management, LLC338,3730.24%$3.7M+97%
SummitTX Capital, L.P.326,6480.23%$3.6MNew
Schonfeld Strategic Advisors LLC269,3480.19%$3MNew
UBS Group AG243,1520.17%$2.7M-2%
BlackRock, Inc.219,9170.16%$2.4M+7%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No SLN insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SLN short interest

Low short interest. 1.3% of SLN shares are sold short: about 1 share in 77. Over the last 12 reports the number of shares short went up 22%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.42M SLN shares were sold short, 1.3% of the shares outstanding, down 17.4% from the report before. At the average daily volume of 9.22M shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

1.30%May 15Oct 301.81%

Days to cover

1.0May 15Oct 3012.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.42M1.30%-17%9.22M1.0
Oct 15, 20262.93M1.57%+15%1.27M2.3
Sep 30, 20262.54M1.36%+17%827,1013.1
Sep 15, 20262.18M1.54%-11%861,1992.5
Aug 31, 20262.44M1.72%+0%695,2043.5
Aug 14, 20262.43M1.72%+32%2.89M1.0
Jul 31, 20261.84M1.30%+17%560,2703.3
Jul 15, 20261.57M1.11%-9%499,8063.1
Jun 30, 20261.73M1.22%-16%772,8262.2
Jun 15, 20262.07M1.46%+0%241,1688.6
May 29, 20262.06M1.45%+4%225,1409.1
May 15, 20261.99M1.40%-8%181,91310.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Silence Therapeutics company events

Silence Therapeutics filed 14 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Oct 19, 2026.

  1. Oct 19, 2026AgreementSilence Therapeutics plc, a public limited company incorporated in England and Wales, entered into a transaction agreement with Merck KGaA, Darmstadt, Germany, a German corporation with general partners. Filing
  2. Aug 12, 2026AgreementSilence Therapeutics plc entered into an underwriting agreement with Jefferies LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters set forth therein, to issue and sell 12,962,963 American Depositary Shares of the Company, each representing three ordinary shares, nominal… Filing
  3. Aug 10, 2026AnnouncementThe Company issued a press release announcing positive topline results from the Phase 2 SANRECO trial, a 36-week, randomized, double-blind, placebo-controlled portion of the Phase 2 trial evaluating divesiran (6 mg/kg) administered subcutaneously every six weeks or every twelve weeks met its… Filing
  4. Aug 10, 2026ResultsReleased financial results. Filing
  5. Jul 16, 2026LeadershipAmended an earlier report. Of the Current Report on Form 8-K filed on December 15, 2025 to disclose information regarding material modifications to a material compensatory plan, contract or arrangement as to which a named executive officer of the registrant participates that were effected pursuant to an agreement entered… Filing
  6. Jun 23, 2026AnnouncementShared information with investors. Filing
  7. Jun 16, 2026VoteReported shareholder vote results. Filing
  8. Jun 11, 2026AnnouncementSilence Therapeutics plc issued a press release highlighting follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6, in 21 phlebotomy-dependent patients with polycythemia vera (PV) presented at the European Hematology… Filing
  9. May 18, 2026AgreementSilence Therapeutics plc entered into an Open Market Sale Agreement SM with Jefferies LLC. Filing
  10. May 7, 2026ResultsReleased financial results. Filing
  11. Mar 5, 2026ResultsReleased financial results. Filing
  12. Dec 22, 2025LeadershipAmended an earlier report. Update Regarding Principal Executive Officer Compensation Arrangement As previously disclosed in the Original Report, Iain Ross, Chairman of the Board, was appointed as interim principal executive officer of the Company, effective December 14, 2025. Filing
  13. Dec 22, 2025LeadershipThe Board of Directors of Silence Therapeutics plc appointed Rhonda Hellums, the Company’s Executive Vice President and Chief Financial Officer, to the Board, effectively immediately. Filing
  14. Dec 15, 2025LeadershipSilence Therapeutics plc announced that Craig Tooman, who has served as the Company’s President, Chief Executive Officer and a member of the Company’s Board of Directors since 2022, agreed by mutual consent to end his employment with the Company and step down from the Board effective December 14… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Silence Therapeutics financials

Famous investors that hold SLN

6 of the 50 well-known investors we track reported holding SLN in their latest 13F filing. The largest position is Ken Griffin's, worth $30.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20262.83M$30.9M0.0%+113%
Israel Englander · Millennium ManagementQ3 20261.45M$15.9M0.0%+60%
Jim Simons · Renaissance TechnologiesQ3 2026152,200$1.7M0.0%+799%
George Soros · Soros Fund ManagementQ3 2026100,000$1.1M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202644,252$484K0.0%New
Steve Cohen · Point72 Asset ManagementQ3 202640,192$439K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named SLN in the last 120 days.

FiledHolderFormStake
Nov 16, 2026TCG Crossover GP I, LLC13G/A3.9%
Nov 16, 2026TCG Crossover GP I, LLC13G/A3.9%
Nov 12, 2026Invus Public Equities, L.P.13G/A4.1%
Nov 12, 2026Invus Public Equities, L.P.13G/A4.1%
Nov 5, 2026FMR LLC13G7.1%
Nov 5, 2026FMR LLC13G7.1%
Oct 13, 2026Tetragon Financial Group Limited13G5.2%
Oct 13, 2026Tetragon Financial Group Limited13G5.2%
Oct 13, 2026Tetragon Financial Group Limited13G/A5.3%
Oct 13, 2026Tetragon Financial Group Limited13G/A5.3%

Questions about Silence Therapeutics plc (SLN) stock

Who owns the most SLN stock?

The largest reported owner of Silence Therapeutics plc (SLN) is Siren, L.L.C., with 2.3% of the company. In total, 69 funds and institutions reported holding SLN at the end of Q2 2026, together about 16% of the shares. See the largest owners.

Are SLN insiders buying or selling?

No SLN insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in SLN?

As of Oct 30, 2026, 2.42M SLN shares were sold short, 1.3% of the shares outstanding, down 17.4% from the report before. At the average daily volume of 9.22M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold SLN?

6 of the 50 well-known investors we track reported SLN in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $30.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.